In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
Ovarian Cancer Research Alliance Reports Year of Significant Progress Across Research, Advocacy, and Patient Support
Organization launches global initiatives, expands patient programs, strengthens policy leadership, and achieves record engagement in 2025 NEW YORK, NY — [January 13, 2026] — In 2025, Ovarian Cancer Research Alliance (OCRA) delivered a year defined by action—launching new global research initiatives, expanding support and education programs, strengthening advocacy and policy leadership, and setting new records for engagement across … Continued
In Loving Memory of Elle Simone Scott
We mourn the loss of Elle Simone Scott—a force of creativity, generosity, and purpose whose influence reached far beyond the kitchen. As tributes continue to pour in from across the culinary world, creative industries, and advocacy spaces, it is clear just how deeply Elle touched lives through her work, her mentorship, and her commitment to equity … Continued
OCRA VP of Policy Featured in Citybiz on Launch of New Center for Public Policy
In a new piece published by citybiz, OCRA’s Vice President, Policy, Chad Ramsey, discusses the launch of OCRA’s Center for Public Policy, highlighting its role in expanding critical advocacy work and bringing more agency to the gynecologic cancer community. Ramsey explains how patient, survivor, and caregiver experiences have helped shape OCRA’s advocacy priorities over the past … Continued